Suppr超能文献

多种药物在不同但相互依存的位点竞争通过恶性疟原虫氯喹抗性转运蛋白进行转运。

Multiple drugs compete for transport via the Plasmodium falciparum chloroquine resistance transporter at distinct but interdependent sites.

作者信息

Bellanca Sebastiano, Summers Robert L, Meyrath Max, Dave Anurag, Nash Megan N, Dittmer Martin, Sanchez Cecilia P, Stein Wilfred D, Martin Rowena E, Lanzer Michael

机构信息

From the Department of Infectious Diseases, Parasitology, Heidelberg University, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.

the Research School of Biology, Australian National University, Canberra, Australian Capital Territory 0200, Australia, and.

出版信息

J Biol Chem. 2014 Dec 26;289(52):36336-51. doi: 10.1074/jbc.M114.614206. Epub 2014 Nov 6.

Abstract

Mutations in the "chloroquine resistance transporter" (PfCRT) are a major determinant of drug resistance in the malaria parasite Plasmodium falciparum. We have previously shown that mutant PfCRT transports the antimalarial drug chloroquine away from its target, whereas the wild-type form of PfCRT does not. However, little is understood about the transport of other drugs via PfCRT or the mechanism by which PfCRT recognizes different substrates. Here we show that mutant PfCRT also transports quinine, quinidine, and verapamil, indicating that the protein behaves as a multidrug resistance carrier. Detailed kinetic analyses revealed that chloroquine and quinine compete for transport via PfCRT in a manner that is consistent with mixed-type inhibition. Moreover, our analyses suggest that PfCRT accepts chloroquine and quinine at distinct but antagonistically interacting sites. We also found verapamil to be a partial mixed-type inhibitor of chloroquine transport via PfCRT, further supporting the idea that PfCRT possesses multiple substrate-binding sites. Our findings provide new mechanistic insights into the workings of PfCRT, which could be exploited to design potent inhibitors of this key mediator of drug resistance.

摘要

“氯喹抗性转运蛋白”(PfCRT)的突变是恶性疟原虫产生耐药性的主要决定因素。我们之前已经表明,突变型PfCRT会将抗疟药物氯喹转运至远离其靶点的位置,而野生型PfCRT则不会。然而,对于其他药物通过PfCRT的转运情况或PfCRT识别不同底物的机制,我们了解甚少。在此我们表明,突变型PfCRT还能转运奎宁、奎尼丁和维拉帕米,这表明该蛋白表现为一种多药耐药载体。详细的动力学分析表明,氯喹和奎宁通过PfCRT进行转运时存在竞争,其方式符合混合型抑制。此外,我们的分析表明,PfCRT在不同但相互拮抗的位点接受氯喹和奎宁。我们还发现维拉帕米是氯喹通过PfCRT转运的部分混合型抑制剂,这进一步支持了PfCRT具有多个底物结合位点的观点。我们的研究结果为PfCRT的作用机制提供了新的见解,可用于设计针对这种耐药性关键介质的有效抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/220c/4276893/2d31fc405161/zbc0031504910001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验